Semba J, Watanabe A, Kito S, Toru M
Division of Health Sciences, University of the Air, Chiba, Japan.
Neuropharmacology. 1995 Jul;34(7):785-91. doi: 10.1016/0028-3908(95)00059-f.
OPC-14597 is a new antipsychotic drug with a unique pharmacological profile. In a behavioural study in rats OPC-14597 did not show cataleptogenic activity even at the highest dose (40 mg/kg, i.p.), whereas it antagonized apomorphine-induced stereotypy dose-dependently (0.5-40 mg/kg). In vivo microdialysis showed that extracellular dopamine (DA) in the striatum was decreased significantly after OPC-14597 administration at higher doses of 10 and 40 mg/kg. Similar results were obtained in extracellular dopamine concentration in the frontal cortex, although the changes in DOPAC and HVA concentrations were smaller than those in the striatum. OPC-14597 also antagonized DA increase induced by the DA autoreceptor antagonist (+)-AJ76. These results that OPC-14597 acts either as an antagonist at postsynaptic dopamine receptors or as an agonist at presynaptic dopamine autoreceptors.
OPC - 14597是一种具有独特药理学特性的新型抗精神病药物。在一项对大鼠的行为学研究中,即使在最高剂量(40毫克/千克,腹腔注射)下,OPC - 14597也未表现出致僵活性,而它能剂量依赖性地拮抗阿扑吗啡诱导的刻板行为(0.5 - 40毫克/千克)。体内微透析显示,在给予10和40毫克/千克的较高剂量OPC - 14597后,纹状体中的细胞外多巴胺(DA)显著降低。在额叶皮质的细胞外多巴胺浓度方面也获得了类似结果,尽管3,4 - 二羟基苯乙酸(DOPAC)和高香草酸(HVA)浓度的变化比纹状体中的变化小。OPC - 14597还拮抗了由多巴胺自身受体拮抗剂(+)- AJ76诱导的多巴胺增加。这些结果表明,OPC - 14597要么作为突触后多巴胺受体的拮抗剂,要么作为突触前多巴胺自身受体的激动剂发挥作用。